Lucentis Improves Vision As Well As Slowing Vision Loss
Featured ArticleMain Category: Eye Health / Blindness
Also Included In: Seniors / Aging; Clinical Trials / Drug Trials
Article Date: 05 Oct 2006 - 10:00 PDT
| Patient / Public: | ![]() |
4.26 (19 votes) |
| Healthcare Prof: | ![]() |
4 (3 votes) |
Lucentis, a drug used to treat wet age-related macular degeneration (wet AMD) was found to not only slow down vision loss in 90% of patients, but it also helped 26% of them get some of their vision back, say Lucentis makers, Genentech, Inc.
Wet AMD is the leading cause of blindness among the elderly.
Lucentis prevents the formation of abnormal, new blood vessels in the eye. It also destroys blood vessels in the eye which have started to leak.
You can read about the latest studies in The New England Journal of Medicine (NEJM).
In one study, 716 volunteers underwent an eye chart test. They all suffered from AMD. Half the group received Lucentis injection, while the other half received a placebo injection.Two years later:
-- 90% of the Lucentis patients lost fewer than 15 letters on the eye chart test
-- 50% of the placebo patients lost fewer than 15 letters on the eye chart test
-- 26% of patients who received 0.3mg of Lucentis experienced improvement in their eyesight*
-- 33% of patients who received 0.5mg of Lucentis experienced improvement in their eyesight*
-- 4% of patients who received the placebo experienced improvement in their eyesight*
* Improvement = Being able to read 15 more letters on the eye chart test
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld, M.D., Ph.D., David M. Brown, M.D., Jeffrey S. Heier, M.D., David S. Boyer, M.D., Peter K. Kaiser, M.D., Carol Y. Chung, Ph.D., Robert Y. Kim, M.D., for the MARINA Study Group
NEJM Volume 355:1419-1431 - October 5, 2006 - Number 14
Click here to see abstract online
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
David M. Brown, M.D., Peter K. Kaiser, M.D., Mark Michels, M.D., Gisele Soubrane, M.D., Jeffrey S. Heier, M.D., Robert Y. Kim, M.D., Judy P. Sy, Ph.D., Susan Schneider, M.D., for the ANCHOR Study Group
NEJM Volume 355:1432-1444 - October 5, 2006 - Number 14
Click here to see abstract online
Written by: Christian Nordqvist
Editor: Medical News Today
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/articles/53457.php>
APA
http://www.medicalnewstoday.com/articles/53457.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




